Revolution Medicines, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Revolution Medicines, Inc. (RVMD) had Deferred Tax Assets, Operating Loss Carryforwards of $435.59 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $435.59M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $226.50M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $147.58M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $132.08M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $435.59M 10-K · filed 2026-02-25 |
| 2024-12-31 | $226.50M 10-K · filed 2026-02-25 |
| 2023-12-31 | $147.58M 10-K · filed 2025-02-26 |
| 2022-12-31 | $132.08M 10-K · filed 2024-02-26 |
| 2021-12-31 | $123.99M 10-K · filed 2023-02-27 |
| 2020-12-31 | $74.14M 10-K · filed 2022-02-28 |
| 2019-12-31 | $38.51M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |